Compounds > cabergoline
Page last updated: 2024-08-23

cabergoline and cyc 202

cabergoline has been researched along with cyc 202 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Feelders, RA; Hofland, LJ; Lacroix, A; Newell-Price, J; Nieman, LK; Pivonello, R1
Reincke, M; Theodoropoulou, M1

Reviews

2 review(s) available for cabergoline and cyc 202

ArticleYear
Advances in the medical treatment of Cushing's syndrome.
    The lancet. Diabetes & endocrinology, 2019, Volume: 7, Issue:4

    Topics: ACTH Syndrome, Ectopic; ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenal Gland Neoplasms; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cabergoline; Cushing Syndrome; Dopamine Agonists; ErbB Receptors; Gefitinib; Hormones; Humans; Imidazoles; Isoquinolines; Molecular Targeted Therapy; Pituitary ACTH Hypersecretion; Pyrazoles; Pyridines; Receptors, Glucocorticoid; Roscovitine; Somatostatin; Temozolomide; Tretinoin

2019
Tumor-Directed Therapeutic Targets in Cushing Disease.
    The Journal of clinical endocrinology and metabolism, 2019, 03-01, Volume: 104, Issue:3

    Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antineoplastic Agents; Cabergoline; Clinical Trials as Topic; Corticotrophs; Humans; Pituitary ACTH Hypersecretion; Roscovitine; Silybin; Somatostatin; Treatment Outcome; Tretinoin

2019